XOMA Royalty (NASDAQ:XOMA) Sets New 1-Year High – Here’s Why

XOMA Royalty Corporation (NASDAQ:XOMA)’s share price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $44.01 and last traded at $43.89, with a volume of 144744 shares trading hands. The stock had previously closed at $43.85.

Analysts Set New Price Targets

Several brokerages have recently weighed in on XOMA. Benchmark cut shares of XOMA Royalty from a “buy” rating to a “hold” rating in a research note on Friday, May 22nd. HC Wainwright downgraded shares of XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 target price for the company. in a research report on Thursday, April 30th. Lucid Cap Mkts lowered shares of XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings raised shares of XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 29th. Finally, Zacks Research upgraded shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th. One equities research analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, XOMA Royalty has an average rating of “Hold” and an average price target of $53.75.

XOMA Royalty Trading Up 0.1%

The company has a debt-to-equity ratio of 0.96, a quick ratio of 3.59 and a current ratio of 3.59. The firm has a fifty day moving average price of $41.93 and a 200 day moving average price of $33.32. The company has a market cap of $550.38 million, a price-to-earnings ratio of 27.96 and a beta of 0.86.

XOMA Royalty (NASDAQ:XOMA) last posted its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.02). XOMA Royalty had a return on equity of 12.56% and a net margin of 53.46%.The firm had revenue of $12.32 million for the quarter, compared to the consensus estimate of $13.91 million. As a group, equities analysts predict that XOMA Royalty Corporation will post 0.9 EPS for the current fiscal year.

Hedge Funds Weigh In On XOMA Royalty

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. State of Alaska Department of Revenue bought a new stake in XOMA Royalty in the fourth quarter valued at approximately $27,000. Russell Investments Group Ltd. boosted its stake in shares of XOMA Royalty by 3,436.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 756 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of XOMA Royalty by 203.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,523 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 543 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in XOMA Royalty in the 2nd quarter valued at $116,000. Institutional investors own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.